Spravato is a brand name for esketamine, a nasal spray medication that has been approved by the US Food and Drug Administration (FDA) for the treatment of treatment-resistant depression. Esketamine is a derivative of ketamine, a dissociative anesthetic that has been used for many years in medical settings.

Spravato is typically administered in a healthcare provider’s office or clinic, and it is only available through a restricted distribution program due to its potential for abuse and misuse. The medication is used in conjunction with an oral antidepressant medication, and it is typically recommended for people who have not responded to at least two other antidepressant treatments.

Esketamine works by blocking N-methyl-D-aspartate (NMDA) receptors in the brain, which leads to an increase in the levels of glutamate, a neurotransmitter involved in learning and memory. This increase in glutamate levels may help to restore the brain’s ability to regulate mood.

While esketamine has been shown to produce rapid and significant improvements in depression symptoms, it does come with potential side effects, including sedation, dissociation, dizziness, and nausea. As with any medication, it is important to discuss the risks and benefits with a healthcare provider before starting treatment with Spravato.

ROW Psychiatric services offers Spravato strictly through insurance. Please call today to see if your insurance will cover this treatment.

Blog at WordPress.com.